New trials will investigate rivaroxaban, the most studied Factor Xa inhibitor, for the treatment of acute coronary syndrome (ACS), embolic stroke of undetermined source (ESUS) and peripheral artery
The YUKAWA-2 (StudY of LDL-Cholesterol Reduction Using a Monoclonal PCSK9 Antibody in Japanese Patients With Advanced Cardiovascular Risk) trial met its co-primary endpoints: the percent reduction from baseline
BTG and SciClone previously entered into an agreement granting SciClone exclusive licensing and distribution rights to DC Bead in China. Under the agreement, SciClone will purchase product from
The clinical test are being conducted through Immunotech Laboratories, BG ("IMMB-BG") a 49% owned subsidiary of Immunotech Laboratories. Since 2013, IMMB-BG hired and funded the Clinical Research Organization
The first newly allowed patent application (serial No: 05723389.2) entitled "Systems and Methods for Clonal Expression in Plants," includes claims to a system for generating transgenic hairy root
Following the transaction, Patheon’s biologic drug substance business, a unit of DPx Holdings, will span four facilities in Europe, Australia and North America and include 550 employees globally.
The new facility is designed to help biopharmaceutical companies develop manufacturing processes and find solutions to processing challenges in collaboration with engineers from EMD. EMD Millipore president and
This is its fourth dedicated research centre in South Africa and brings Synexus global site count to 24 with 3 new centres being opened in the last six
The ‘829 patent application includes newly allowed claims directed to compositions comprising a double-stranded molecule of between 19 and 52 nucleotides in each strand with various end configurations,
Using Ayasdi’s patented topological learning technology, Ayasdi Care can examine millions of patient cases across a provider’s own facilities to rapidly ascertain pathways that deliver the highest quality
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.